<DOC>
	<DOCNO>NCT01666301</DOCNO>
	<brief_summary>Background : In simulation base pharmacokinetic model demonstrate increase erythropoiesis stimulating agent ( ESAs ) half-life shorten administration interval decrease hemoglobin variability . The benefit reduce administration interval however lessen variability induce frequent dosage adjustment . The purpose study analyze reticulocyte hemoglobin kinetics different ESAs administration interval collective chronic hemodialysis patient . Methods : The study design open-label , randomize , four-period cross-over investigation , include 30 patient chronic hemodialysis regional hospital Locarno ( Switzerland ) September 2009 last 2 year . Four treatment strategy ( C.E.R.A . every 4 week Q4W every 2 week Q2W , Darbepoetin alfa Q4W Q2W ) compare . The mean square successive difference hemoglobin , reticulocyte count ESAs dose use quantify variability . We distinguish short- long-term variability base respectively weekly monthly successive difference .</brief_summary>
	<brief_title>ESAs , Reticulocyte Dynamic Hemoglobin Variability</brief_title>
	<detailed_description />
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>chronic patient age 18 year old , undergoing dialysis 3 time week least 8 week screen , necessitate continuous subcutaneous treatment weekly Darbepoetin alfa Erythropoietin beta maintain hemoglobin ( Hb ) target pregnancy ; respect inclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Erythropoietin stimulating agent</keyword>
	<keyword>Hemoglobin</keyword>
	<keyword>Reticulocytes</keyword>
	<keyword>Variability</keyword>
</DOC>